Patents by Inventor Gjalt W. Huisman

Gjalt W. Huisman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Ketoreductase polypeptides for the production of (R)-3-hydroxythiolane
    Patent number: 11427841
    Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize chiral compounds.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: August 30, 2022
    Assignee: Codexis, Inc.
    Inventors: Jack S Liang, Stephan Jenne, Emily Mundorff, Rama Voladri, James J. Lalonde, Gjalt W. Huisman
  • Engineered tyrosine ammonia lyase
    Patent number: 11421253
    Abstract: The present invention provides engineered tyrosine ammonia-lyase (TAL) polypeptides and compositions thereof. In some embodiments, the engineered TAL polypeptides have been optimized to provide enhanced catalytic activity and enhanced acid stability, while reducing sensitivity to proteolysis and increasing tolerance to acidic pH levels. The invention also provides methods for utilization of the compositions comprising the engineered TAL polypeptides for therapeutic and industrial purposes.
    Type: Grant
    Filed: January 14, 2021
    Date of Patent: August 23, 2022
    Assignee: Codexis, Inc.
    Inventors: Gjalt W. Huisman, Joyce Liu, Nikki Dellas, Chinping Chng, William Casey Hallows
  • Engineered phenylalanine ammonia lyase polypeptides
    Patent number: 11401515
    Abstract: The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: August 2, 2022
    Assignee: Codexis, Inc.
    Inventors: Gjalt W. Huisman, Nicholas J. Agard, Benjamin Mijts, Jonathan Vroom, Xiyun Zhang
  • Engineered imine reductases and methods for the reductive amination of ketone and amine compounds
    Patent number: 11377673
    Abstract: The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: July 5, 2022
    Assignee: Codexis, Inc.
    Inventors: Haibin Chen, Steven J. Collier, Jovana Nazor, Joly Sukumaran, Derek Smith, Jeffrey C. Moore, Gregory Hughes, Jacob Janey, Gjalt W. Huisman, Scott J. Novick, Nicholas J. Agard, Oscar Alvizo, Gregory A. Cope, Wan Lin Yeo, Stefanie Ng Minor
  • T7 RNA POLYMERASE VARIANTS
    Publication number: 20220186197
    Abstract: The present invention provides engineered RNA polymerase variants and compositions comprising these variants. The present invention further provides engineered T7 RNA polymerase variants and compositions comprising these variants. These variants have been evolved for selective incorporation of the m7G(5?)ppp(5?)m7G cap analog over GTP at the initiation of in vitro transcription. The present invention also provides methods for selective capping of RNA transcripts.
    Type: Application
    Filed: December 21, 2021
    Publication date: June 16, 2022
    Inventors: Mathew G. Miller, Chinping Chng, Oscar Alvizo, Melissa Ann Mayo, James Nicholas Riggins, Xiang Yi, Jonathan S. Penfield, Gjalt W. Huisman, Jared Davis, Yasushi Saotome
  • Human alpha-galactosidase variants
    Patent number: 11278600
    Abstract: The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved stability under both acidic (pH<4.5) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: March 22, 2022
    Assignee: Codexis, Inc.
    Inventors: Nicholas J. Agard, Mathew G. Miller, Xiyun Zhang, Gjalt W. Huisman
  • T7 RNA polymerase variants
    Patent number: 11236312
    Abstract: The present invention provides engineered RNA polymerase variants and compositions comprising these variants. The present invention further provides engineered T7 RNA polymerase variants and compositions comprising these variants. These variants have been evolved for selective incorporation of the m7G(5?)ppp(5?)m7G cap analog over GTP at the initiation of in vitro transcription. The present invention also provides methods for selective capping of RNA transcripts.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: February 1, 2022
    Assignee: Codexis, Inc.
    Inventors: Mathew G. Miller, Chinping Chng, Oscar Alvizo, Melissa Ann Mayo, James Nicholas Riggins, Xiang Yi, Jonathan S. Penfield, Gjalt W. Huisman, Jared Davis, Yasushi Saotome
  • T7 RNA polymerase variants
    Patent number: 11236311
    Abstract: The present invention provides engineered RNA polymerase variants and compositions comprising these variants. The present invention further provides engineered T7 RNA polymerase variants and compositions comprising these variants. These variants have been evolved for selective incorporation of the m7G(5?)ppp(5?)m7G cap analog over GTP at the initiation of in vitro transcription. The present invention also provides methods for selective capping of RNA transcripts.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: February 1, 2022
    Assignee: Codexis, Inc.
    Inventors: Mathew G. Miller, Chinping Chng, Oscar Alvizo, Melissa Ann Mayo, James Nicholas Riggins, Xiang Yi, Jonathan S. Penfield, Gjalt W. Huisman, Jared Davis, Yasushi Saotome
  • ENONE REDUCTASES
    Publication number: 20210324344
    Abstract: The disclosure relates to engineered enone reductase polypeptides having improved properties, polynucleotides encoding the engineered polypeptides, related vectors, host cells, and methods for making the engineered enone reductase polypeptides. The disclosure also provides methods of using the engineered enone reductase polypeptides for chemical transformations.
    Type: Application
    Filed: March 30, 2021
    Publication date: October 21, 2021
    Inventors: Christopher K. Savile, Vesna Mitchell, Xiyun Zhang, Gjalt W. Huisman
  • Engineered phenylalanine ammonia lyase polypeptides
    Patent number: 11136571
    Abstract: The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: October 5, 2021
    Assignee: Codexis, Inc.
    Inventors: Gjalt W. Huisman, Nicholas J. Agard, Benjamin Mijts, Jonathan Vroom, Xiyun Zhang
  • Engineered phenylalanine ammonia lyase polypeptides
    Patent number: 11130947
    Abstract: The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: September 28, 2021
    Assignee: Codexis, Inc.
    Inventors: Gjalt W. Huisman, Nicholas J. Agard, Benjamin Mijts, Jonathan Vroom, Xiyun Zhang
  • ENGINEERED BRANCHED CHAIN KETOACID DECARBOXYLASES
    Publication number: 20210269789
    Abstract: The present invention provides engineered branched chain ketoacid decarboxylase (KdcA) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered branched chain ketoacid decarboxylase (KdcA) polypeptides. In some embodiments, the engineered KdcA polypeptides are optimized to provide enhanced catalytic activity, as well as reduced sensitivity to proteolysis and increased tolerance to storage at elevated temperatures. The present invention also provides methods for the use of the compositions comprising the engineered KdcA polypeptides for therapeutic and industrial purposes.
    Type: Application
    Filed: June 27, 2019
    Publication date: September 2, 2021
    Inventors: Xiang Yi, Nikki Dellas, James Nicholas Riggins, Chinping Chng, Nicholas J. Agard, Kristen Jean Vallieu, Gjalt W. Huisman
  • ENGINEERED TYROSINE AMMONIA LYASE
    Publication number: 20210254041
    Abstract: The present invention provides engineered tyrosine ammonia-lyase (TAL) polypeptides and compositions thereof. In some embodiments, the engineered TAL polypeptides have been optimized to provide enhanced catalytic activity while reducing sensitivity to proteolysis and increasing tolerance to acidic pH levels. The invention also provides methods for utilization of the compositions comprising the engineered TAL polypeptides for therapeutic and industrial purposes.
    Type: Application
    Filed: April 27, 2021
    Publication date: August 19, 2021
    Inventors: Gjalt W. Huisman, Nicholas J. Agard, David Elgart, Xiyun Zhang
  • HUMAN ALPHA-GALACTOSIDASE VARIANTS
    Publication number: 20210244804
    Abstract: The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved stability under both acidic (pH<4.5) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.
    Type: Application
    Filed: March 9, 2021
    Publication date: August 12, 2021
    Inventors: Nicholas J. Agard, Mathew G. Miller, Xiyun Zhang, Gjalt W. Huisman
  • ENGINEERED PHENYLALANINE AMMONIA LYASE POLYPEPTIDES
    Publication number: 20210222146
    Abstract: The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides.
    Type: Application
    Filed: April 1, 2021
    Publication date: July 22, 2021
    Inventors: Gjalt W. Huisman, Nicholas J. Agard, Benjamin Mijts, Jonathan Vroom, Xiyun Zhang
  • ENGINEERED PHENYLALANINE AMMONIA LYASE POLYPEPTIDES
    Publication number: 20210222145
    Abstract: The present invention provides engineered phenylalanine ammonia lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia lyase (PAL) polypeptides. In some embodiments, the engineered PAL polypeptides are optimized to provide enhanced catalytic activity, as well as reduced sensitivity to proteolysis and increased tolerance to storage at elevated temperatures. In some embodiments, the engineered PAL polypeptides contain fewer phenylalanine residues than wild-type PAL polypeptides. The present invention also provides methods for the use of the compositions comprising the engineered PAL polypeptides for therapeutic and industrial purposes.
    Type: Application
    Filed: March 31, 2021
    Publication date: July 22, 2021
    Inventors: Chinping Chng, William Casey Hallows, Nicholas J. Agard, Oscar Alvizo, Nikki Dellas, Gjalt W. Huisman, John Joseph Nicols
  • ENGINEERED ACID ALPHA-GLUCOSIDASE VARIANTS
    Publication number: 20210189365
    Abstract: The present invention provides engineered acid alpha-glucosidase (GAA) polypeptides and compositions thereof. In some embodiments, the engineered GAA polypeptides have been optimized to provide increased expression, stability at neutral pH, and activity in cell lysates. The invention also provides methods for utilization of the compositions comprising the engineered GAA polypeptides for therapeutic and other purposes.
    Type: Application
    Filed: December 18, 2020
    Publication date: June 24, 2021
    Inventors: William Casey Hallows, Rachel Cathleen Botham, Yu Zhu, Chinping Chng, Nikki Dellas, Gjalt W. Huisman, Moulay Hicham Alaoui Ismaili, David William Homan, Adam P. Silverman, Jonathan Vroom, Jessica P. Lao
  • Polynucleotides encoding engineered tyrosine ammonia lyase variants
    Patent number: 11015184
    Abstract: The present invention provides engineered tyrosine ammonia-lyase (TAL) polypeptides and compositions thereof. In some embodiments, the engineered TAL polypeptides have been optimized to provide enhanced catalytic activity while reducing sensitivity to proteolysis and increasing tolerance to acidic pH levels. The invention also provides methods for utilization of the compositions comprising the engineered TAL polypeptides for therapeutic and industrial purposes.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: May 25, 2021
    Assignee: Codexis, Inc.
    Inventors: Gjalt W. Huisman, Nicholas J. Agard, David Elgart, Xiyun Zhang
  • KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
    Publication number: 20210139861
    Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize a variety of chiral compounds.
    Type: Application
    Filed: January 14, 2021
    Publication date: May 13, 2021
    Inventors: Jack Liang, Stephane J. Jenne, Emily Mundorff, Charlene Ching, John M. Gruber, Anke Krebber, Gjalt W. Huisman
  • ENGINEERED TYROSINE AMMONIA LYASE
    Publication number: 20210130855
    Abstract: The present invention provides engineered tyrosine ammonia-lyase (TAL) polypeptides and compositions thereof. In some embodiments, the engineered TAL polypeptides have been optimized to provide enhanced catalytic activity and enhanced acid stability, while reducing sensitivity to proteolysis and increasing tolerance to acidic pH levels. The invention also provides methods for utilization of the compositions comprising the engineered TAL polypeptides for therapeutic and industrial purposes.
    Type: Application
    Filed: January 14, 2021
    Publication date: May 6, 2021
    Inventors: Gjalt W. Huisman, Joyce Liu, Nikki Dellas, Chinping Chng, William Casey Hallows